You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary mediastinal diffuse large cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

Available
  • Large B-cell Lymphoma
  • +4 more
  • Epcoritamab
  • (no location specified)
Feb 16, 2023

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +8 more
  • Anakinra
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

Withdrawn
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Lentiviral-based Gene-edited Immune Cell Therapy

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • Pell's lentiviral-based gene-edited immune cell therapy
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • La Jolla, California
  • +7 more
Aug 25, 2023

Bio-CAR-T BS Study

Recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • +2 more
    • Brescia, Italy
      ASST Spedali Civili di Brescia
    May 5, 2022

    Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • CD19-targeted chimeric antigen receptor T-cell
    • Kaohsiung, Taiwan
    • +2 more
    Oct 25, 2022

    Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

    Not yet recruiting
    • Mature B-Cell Neoplasm
    • +25 more
    • (no location specified)
    Sep 14, 2022

    ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

    Active, not recruiting
    • ALK-Positive Large B-Cell Lymphoma
    • +34 more
    • Phoenix, Arizona
    • +32 more
    Jan 3, 2023

    Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

    Completed
    • Multiple Myeloma
    • +7 more
    • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Nov 2, 2022

    Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

    Not yet recruiting
    • Refractory Aggressive B-cell Lymphomas
    • +12 more
    • Boston, Massachusetts
    • +1 more
    Oct 13, 2022

    DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +6 more
    • Axicabtagene Ciloleucel
    • +10 more
    • (no location specified)
    Jan 13, 2023

    Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +14 more
    • Cholecalciferol
    • Laboratory Biomarker Analysis
    • Scottsdale, Arizona
    • +4 more
    Jan 16, 2023

    DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

    Terminated
    Has Results
    • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    • +5 more
    • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 1, 2022

    Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

    Recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +8 more
    • Polatuzumab Vedotin
    • +6 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 26, 2023